Head to Head Survey: Alignment Healthcare (NASDAQ:ALHC) vs. Mangoceuticals (NASDAQ:MGRX)

Mangoceuticals (NASDAQ:MGRX – Get Free Report) and Alignment Healthcare (NASDAQ:ALHC – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Mangoceuticals and Alignment Healthcare, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mangoceuticals 1 0 0 0 1.00
Alignment Healthcare 1 6 6 0 2.38

Alignment Healthcare has a consensus target price of $14.00, suggesting a potential upside of 93.50%. Given Alignment Healthcare’s stronger consensus rating and higher probable upside, analysts plainly believe Alignment Healthcare is more favorable than Mangoceuticals.

Earnings and Valuation

This table compares Mangoceuticals and Alignment Healthcare”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mangoceuticals $315,227.00 10.81 -$20.64 million ($1.01) -0.16
Alignment Healthcare $4.94 billion 0.31 -$720,000.00 $0.13 55.65

Alignment Healthcare has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than Alignment Healthcare, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 86.2% of Alignment Healthcare shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by company insiders. Comparatively, 5.2% of Alignment Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Mangoceuticals and Alignment Healthcare’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mangoceuticals -4,794.60% -96.39% -89.60%
Alignment Healthcare 0.59% 12.46% 2.36%

Risk & Volatility

Mangoceuticals has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, Alignment Healthcare has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.

Summary

Alignment Healthcare beats Mangoceuticals on 11 of the 14 factors compared between the two stocks.

About Mangoceuticals

(Get Free Report)

Mangoceuticals, Inc. is a men’s health and wellness company that offers telehealth services through its online platform. The platform connects customers with healthcare providers for consultations and, when appropriate, prescription treatments. The company’s offerings have included treatments for erectile dysfunction, hair loss and testosterone-related concerns, as well as weight-management services. Prescriptions are fulfilled through pharmacy partners. Mangoceuticals primarily serves customers in the United States through its digital platform.

About Alignment Healthcare

(Get Free Report)

Alignment Healthcare, Inc. is a technology-enabled healthcare company focused primarily on serving older adults through Medicare Advantage plans. Its health plans, offered under the Alignment Health Plan name, combine insurance coverage with care coordination and support intended to address members’ medical and everyday health needs. The company uses a care model that includes personalized care teams, member support and technology to help coordinate services across providers. Its Medicare Advantage offerings include plan options such as HMO and PPO products, with availability and benefits varying by location.

Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.